Clinical Trial: Evaluation of the Metabolic Effects of a Ophiocordyceps Sinensis- and Coenzyme Q10-Based Formulation in Subjects With Mild-to-Moderate Hypercholesterolemia

U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07852481) titled 'Evaluation of the Metabolic Effects of a Ophiocordyceps Sinensis- and Coenzyme Q10-Based Formulation in Subjects With Mild-to-Moderate Hypercholesterolemia' on Sept. 25.

Brief Summary: This randomized, double-blind, placebo-controlled study will evaluate the metabolic effects of CORDICOL, a formulation containing Ophiocordyceps sinensis extract (200 mg) and Coenzyme Q10 (50 mg), in adults with mild-to-moderate hypercholesterolemia. The study will compare CORDICOL with placebo, with LDL cholesterol as the primary outcome and additional assessments of lipid and glucose metabolism, safety, tolerability, and quality of life.

The study w...